COMMUNIQUÉS West-GlobeNewswire

U.S. Oral Surgery Management Enters New Hampshire
10/09/2024
Adds Four New Partner Practices IRVING, Texas, Sept. 10, 2024 (GLOBE NEWSWIRE) -- U.S. Oral Surgery Management (USOSM) has secured four new partner practices, including one in New Hampshire, USOSM’s first partner [...]
Virbac : Declaration of the number of shares and voting rights 08/2024
10/09/2024
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial [...]
Virbac : Déclaration d'actions et de droits de vote 08/2024
10/09/2024
DECLARATION D’ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d’actions composant le capital (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) [...]
Virbac : Declaration of the number of shares and voting rights 07/2024
10/09/2024
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial [...]
Virbac : Déclaration d'actions et de droits de vote 07/2024
10/09/2024
DECLARATION D’ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d’actions composant le capital (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) [...]
Methodist Healthcare Adopts IR-MED’s PressureSafe™ Device for Usability Study: Decision Support Device Aims to Reduce Substantial Healthcare Burden of Pressure Injuries
10/09/2024
Patient enrollment and monitoring with PressureSafe ™ has commenced In a similar study conducted at the world’s 2 nd largest HMO, PressureSafe ™ had efficacy of 92% in detection and the incidence of pressure injuries [...]
WeightWatchers Announces Strategic Leadership Team Appointments
10/09/2024
Additions of Chief Commercial Officer and Chief Impact Officer emphasize the Company’s continued focus on growth ahead of 2025 NEW YORK, Sept. 10, 2024 (GLOBE NEWSWIRE) -- WeightWatchers (NASDAQ: WW), (“WeightWatchers [...]
Tersa Earth Partners with Wet’suwet’en First Nation to Advance Sustainable Economic Growth
10/09/2024
BURNS LAKE, British Columbia, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Tersa Earth Innovations Inc. is excited to announce a strategic partnership with Yinka Dene Economic Development Limited Partnership (YLP), the economic [...]
ARS Pharmaceuticals Submits sNDA to FDA for neffy® 1 mg Dose for Pediatric Patients with Type I Allergic Reactions Who Weigh 15 to 30 kg (33-66 lbs.)
09/09/2024
If approved, neffy 1 mg will be the first and only needle-free epinephrine treatment available for younger school-aged children The submission of neffy 1 mg sNDA follows FDA approval on August 9, 2024, of neffy (2 mg) [...]
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/09/2024
BEDFORD, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on September 3, 2024, Anika granted [...]
Relay Therapeutics Announces Proposed Public Offering of Common Stock
09/09/2024
CAMBRIDGE, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational [...]
New Meta-Analysis Shows Treos Bio’s Promiscuous Epitopes in Their Off-The-Shelf Colorectal Cancer Immunotherapy Produce Stronger Immune Response than Traditional Epitopes
09/09/2024
LONDON, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Treos Bio announced the results of a meta-analysis from three clinical trials evaluating its investigational off-the-shelf immunotherapy, PolyPEPI1018, for the treatment of [...]
UPDATE - IMUNON’s Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management
09/09/2024
September 18 th Event in New York City to Include a Review of the Opportunity for Investigational Therapy IMNN-001 (IL-12) to Treat Advanced Ovarian Cancer and Clinical Development Timeline LAWRENCEVILLE, N.J., Sept. 09 [...]
Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2024
09/09/2024
-- Recorded First Quarter Revenue of $40.2 Million -- -- Signed $66 Million in Net New Business, Resulting in Backlog of $219 Million -- -- Maintained FY2025 Revenue Guidance of Between $160 Million and $168 Million -- [...]
Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
09/09/2024
DOYLESTOWN, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic [...]
BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules
09/09/2024
SUNNYVALE, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced [...]
Trinity Biotech Provides an Update on the Continued Development of Its Continuous Glucose Monitor Technology
09/09/2024
DUBLIN, Ireland, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable [...]
Terns Announces Proposed Public Offering
09/09/2024
FOSTER CITY, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product [...]
Abivax presents first-half 2024 financial results
09/09/2024
Abivax presents first-half 2024 financial results Cash balance of EUR 222M at June 30, 2024; cash runway in to Q4 2025 PARIS, France, September 9, 2024, 10:00 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX [...]

Pages